

Global and regional immunization profile



Data received as of European Region Next overall update Winter 2019 Next WHO UNICEF estimates July 2020

					IVE			
Population data in thou	isands 1							
	2018	2017	2016	2015	2014	2000	1990	1980
Total population	926'911	923'248	919'366	915'412	911'433	866'251	845'992	796'994
Live births	11'139	11'243	11'327	11'388	11'425	10'245	12'549	13'363
Surviving infants	11'058	11'157	11'236	11'293	11'324	10'061	12'203	12'871
Pop. less than 5 years	56'743	56'918	57'050	57'161	57'004	51'135	64'186	63'850
Pop. less than 15 years	167'678	166'347	164'902	163'485	161'954	172'232	192'087	192'390
Female 15-49 years	429'832	431'366	433'024	434'851	437'041	442'218	418'958	396'607
Number of reported cas	ses							
Diphtheria	73	35	47	59	35	1'585	3'202	618
Japanese encephalitis	0	3	0	1	1	-	-	-
Measles	82'523	24'356	4'363	25'965	14'176	37'421	234'827	851'849
Mumps	19'845	26'803	20'874	10'027	10'807	243'344	-	-
Pertussis	55'767	63'037	69'490	43'615	43'858	53'675	129'735	90'546
Polio	0	0	0	2	0	0	370	549
Rubella	798	842	1'471	655	653	621'039	_	_
Rubella (CRS)	14	17	6	14	28	47	_	_
Tetanus (neonatal)	0	0	0	1	1	27	69	26
Tetanus (total)	81	134	137	122	68	412	879	1'715
Yellow fever	4	0	1	0	0	0	_	_
D 4 64 4	1 41		4 •					
Percentage of target pop based on WHO-UNICED TT2plus is based on repo	F estimates	cinated, b	y antigen					
based on WHO-UNICEL TT2plus is based on repo	F estimates	ecinated, b	y antigen	90	90	93	84	20
based on WHO-UNICED TT2plus is based on repo	F estimates orted coverage	,			90 96	93 96	84 89	
based on WHO-UNICED TT2plus is based on repe BCG DTP1	F estimates orted coverage	92	92	90				70
based on WHO-UNICED TT2plus is based on repe BCG DTP1	F estimates orted coverage 93 97	92 97	92 96	90 96	96	96	89	20 70 63
based on WHO-UNICED TT2plus is based on repe BCG DTP1 DTP3 HepB_BD	F estimates orted coverage 93 97 94	92 97 94	92 96 92	90 96 93	96 93	96 93	89 80	70
based on WHO-UNICED TT2plus is based on repo BCG DTP1 DTP3	93 97 94 39	92 97 94 39	92 96 92 40	90 96 93 41	96 93 41	96 93 13	89 80	70
based on WHO-UNICED TT2plus is based on repo BCG DTP1 DTP3 HepB_BD HepB3 Hib3	93 97 94 39 84	92 97 94 39 83	92 96 92 40 82	90 96 93 41 82	96 93 41 81	96 93 13 42	89 80 - 0	70
based on WHO-UNICED TT2plus is based on repo BCG DTP1 DTP3 HepB_BD HepB3 Hib3	93 97 94 39 84 76	92 97 94 39 83 76	92 96 92 40 82 76	90 96 93 41 82 76	96 93 41 81	96 93 13 42	89 80 - 0	70 63 - - -
based on WHO-UNICED TT2plus is based on repo BCG DTP1 DTP3 HepB_BD HepB3 Hib3 IPV1	93 97 94 39 84 76 85	92 97 94 39 83 76 71	92 96 92 40 82 76 73	90 96 93 41 82 76 69	96 93 41 81 77	96 93 13 42 38	89 80 - 0 0	70 63 - - -
based on WHO-UNICED TT2plus is based on report BCG DTP1 DTP3 HepB_BD HepB3 Hib3 IPV1 MCV1 MCV2	93 97 94 39 84 76 85 95	92 97 94 39 83 76 71 95	92 96 92 40 82 76 73 93	90 96 93 41 82 76 69 94	96 93 41 81 77 - 94	96 93 13 42 38 -	89 80 - 0 0	70 63 - -
based on WHO-UNICED TT2plus is based on report BCG DTP1 DTP3 HepB_BD HepB3 Hib3 IPV1 MCV1 MCV2 PCV3	93 97 94 39 84 76 85 95	92 97 94 39 83 76 71 95 90	92 96 92 40 82 76 73 93 88	90 96 93 41 82 76 69 94 89	96 93 41 81 77 - 94 89	96 93 13 42 38 -	89 80 - 0 0	70 63 - - - - 55
based on WHO-UNICED TT2plus is based on report BCG DTP1 DTP3 HepB_BD HepB3 Hib3 IPV1 MCV1 MCV1 MCV2 PCV3	93 97 94 39 84 76 85 95 91	92 97 94 39 83 76 71 95 90 73	92 96 92 40 82 76 73 93 88 62	90 96 93 41 82 76 69 94 89	96 93 41 81 77 - 94 89 46	96 93 13 42 38 - 91 48	89 80 - 0 0 - 83 -	70 63 - - - - 55 - - - 72
based on WHO-UNICED TT2plus is based on report BCG DTP1 DTP3 HepB_BD HepB3 Hib3 IPV1 MCV1 MCV2 PCV3 Pol3	93 97 94 39 84 76 85 95 91 78	92 97 94 39 83 76 71 95 90 73 93	92 96 92 40 82 76 73 93 88 62 94	90 96 93 41 82 76 69 94 89 48	96 93 41 81 77 - 94 89 46 94	96 93 13 42 38 - 91 48 - 94	89 80 - 0 0 - 83 - - 84	70

Most countries have standard recommendations regarding which vaccines should be offered and at what ages they should be given. In general, vaccines are recommend for the youngest age group at risk for developing the disease whose members are known to respond to the immunization without adverse effects.

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative's Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV). IPV global and regional coverage calculation is for 144 bOPV using countries.

^{1) &}quot;United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.